In conclusion, these results suggest that BUD is effective in controlling asthma inflammation by reducing both T lymphocyte survival and T lymphocyte co-stimulatory ICOS in CD4+/CD25− and by increasing the survival and the activities of CD4+/CD25+ cells. The gene discussed is CD4; the disease is asthma.